Form 4: Cytosorbents CFO Acquires Stock Options Through Salary Reduction Program

Kathleen P. Bloch, CFO of Cytosorbents Corp, acquired 49,038 stock options as part of a voluntary salary reduction program.

Summary

• Kathleen P. Bloch, the Chief Financial Officer of Cytosorbents Corporation, filed a Form 4 on April 2, 2024, reporting a transaction that occurred on March 29, 2024.
• The transaction involved the acquisition of 49,038 stock options (right to buy) at an exercise price of $0.95.
• These stock options were granted as part of a voluntary salary reduction program for the period from April 1, 2024, to December 31, 2024.
• The options were issued under the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan.
• The stock options will vest fully on January 31, 2025, subject to continued service as of the applicable vesting date.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The voluntary salary reduction could be seen as a positive sign of management's commitment, but it's not a major event.

Positives

• The acquisition of stock options by the CFO demonstrates her commitment to the company's long-term success.
• The voluntary salary reduction program suggests a willingness by management to invest in the company's future.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the CFO's participation in the salary reduction program and subsequent stock option grant as a positive sign of alignment with their interests.
• Employees may be impacted by the salary reduction program, depending on its scope and participation rate.

Key Dates